CreativeOne Wealth LLC Sells 1,097 Shares of Halozyme Therapeutics, Inc. $HALO

CreativeOne Wealth LLC reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,559 shares of the biopharmaceutical company’s stock after selling 1,097 shares during the period. CreativeOne Wealth LLC’s holdings in Halozyme Therapeutics were worth $861,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Stevens Capital Management LP acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $235,000. AXQ Capital LP bought a new position in Halozyme Therapeutics in the second quarter valued at about $385,000. Legal & General Group Plc raised its stake in Halozyme Therapeutics by 7.5% during the second quarter. Legal & General Group Plc now owns 337,567 shares of the biopharmaceutical company’s stock worth $17,560,000 after acquiring an additional 23,475 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Halozyme Therapeutics during the second quarter worth about $1,252,000. Finally, Catalyst Funds Management Pty Ltd bought a new position in shares of Halozyme Therapeutics in the second quarter worth about $2,096,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Nicole Labrosse sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares in the company, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $50,721,994.47. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 110,227 shares of company stock worth $8,028,955. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Down 0.2%

Shares of HALO opened at $72.66 on Friday. The stock’s 50-day moving average price is $69.38 and its two-hundred day moving average price is $63.72. Halozyme Therapeutics, Inc. has a 12 month low of $46.26 and a 12 month high of $79.50. The company has a market capitalization of $8.54 billion, a PE ratio of 16.63, a PEG ratio of 0.35 and a beta of 1.18. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm’s revenue was up 22.1% compared to the same quarter last year. During the same period last year, the company earned $1.27 earnings per share. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on HALO. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a report on Wednesday, August 6th. The Goldman Sachs Group boosted their target price on shares of Halozyme Therapeutics from $54.00 to $56.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 18th. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a report on Tuesday, October 14th. Citizens Jmp raised their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, October 21st. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.10.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.